. For ABCG2, however, there is a scarcity of selective inhibitors available for in vivo use (Lee et al., 2015) . The fumitremorgin C derivative Ko143 [(3S,6S,12aS)-1,2,3,4,6,7,12,12a-octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1′,2′:1,6]pyrido [3,4-b] indole-3-propanoic acid 1,1-dimethylethyl ester] (Allen et al., 2002 ) is a potent and relatively selective reference ABCG2 inhibitor which is commonly used for in vitro experiments and which has also been used in vivo in preclinical species (Giri et al., 2008; Chen et al., 2009; Wanek et al., 2012; Bakhsheshian et al., 2013) . In addition to being a potent ABCG2 inhibitor with nanomolar half-maximum inhibitory concentrations, Ko143 at higher, micromolar concentrations also inhibits ABCB1 and ABCC1 (Allen et al., 2002; Matsson et al., 2009; Weidner et al., 2015) . Moreover, there is evidence that Ko143 inhibits solute carrier (SLC) transporters of the SLCO family (Karlgren et al., 2012) . Ko143 is rapidly metabolized in vivo through enzymatic hydrolysis of the tert-butyl ester group into its free acid, which was found to lack an inhibitory effect on ABCG2 and ABCB1 (Weidner et al., 2015; Liu et al., 2017) . Although some preliminary data are available on Ko143 tissue distribution in mice (Liu et al., 2012; Liu et al., 2017) , the influence of ABCG2 and ABCB1 on disposition of Ko143 has not yet been systematically assessed. Weidner et al. performed in vitro uptake experiments with low concentrations of [ 3 H]Ko143 in cell lines overexpressing different ABC transporters (ABCG2, Abcg2, ABCB1, Abcb1a and multidrug resistance-associated protein 1, ABCC1) (Weidner et al., 2015) . Whereas there was no difference in cellular accumulation of [ 3 H]Ko143 between ABCB1-, Abcb1a-and ABCC1-overexpressing and control cells, respectively, they found an approximately 2-fold higher accumulation of [ 3 H]Ko143 in ABCG2-and Abcg2-overexpressing cells, which was displaceable by an excess of unlabeled Ko143 or fumitremorgin C. This led them to conclude that Ko143 binds specifically to ABCG2/Abcg2, suggesting a potential utility of Ko143 as a PET tracer for measuring the density of ABCG2 in different tissues (Weidner et al., 2015) . In this work, we performed PET imaging with 11 C-labeled Ko143 in mice to assess the influence of Abcg2 and Abcb1a/b on tissue distribution and excretion of Ko143 and to assess the suitability of [ 11 C]Ko143 as a PET tracer for ABCG2.
Material and methods

Chemicals
Unless otherwise stated, all chemicals were purchased from Merck (Darmstadt, Germany) or Sigma-Aldrich (Schnelldorf, Germany). Ko143 was obtained from Axon Medchem BV (Groningen, The Netherlands). Before each administration, Ko143 was dissolved in dimethyl sulfoxide (DMSO) and diluted with a mixture of sterile water/ polyethylene glycol 300 (PEG300)/polysorbate 80 (65/25/10, v/v/v) to a final DMSO concentration of 5% (v/v). Formulated Ko143 solution was mixed with radiotracer dissolved in the same vehicle and the mixture was injected intravenously (i.v.) into mice at a volume of 4 mL/ kg body weight. The ABCB1 inhibitor tariquidar dimesylate was freshly dissolved in 2.5% (w/v) aqueous (aq.) dextrose solution before each administration and injected i.v. into mice at a volume of 4 mL/kg. [ 11 C] Methane was produced in a PETtrace cyclotron equipped with a methane target system (GE Healthcare, Uppsala, Sweden). [ 11 C]Methyl iodide was prepared in a TRACERlab FX C Pro synthesis module (GE Healthcare) and converted into [
11 C]methyl triflate as described before (Jewett, 1992) . The radiolabeling precursor 9-O-desmethyl-Ko143 was synthesized at the Department of Medicinal Chemistry (University of Vienna) as described elsewhere (Mairinger, 2016) .
Radiotracer synthesis
Using a TracerLab FX C Pro synthesis module, [
11 C]methyl triflate was led into a solution of 9-O-desmethyl-Ko143 (0.15 mg, 0.33 μmol) in acetonitrile (0.3 mL) containing aq. sodium hydroxide solution (2 M, 3 μL, 6 μmol, 18 equivalents). After heating for 5 min at 75°C, the reaction mixture was cooled (40°C), diluted with 10 mM aq. hydrochloric acid (0.7 mL) and injected into a built-in high-performance liquid chromatography (HPLC) system. A Chromolith Performance RP 18-e (100 × 10 mm, 5 μm) HPLC column equipped with a Chromolith RP 18-e guard column (10 × 10 mm) (Merck KGaA, Darmstadt, Germany) was eluted with acetonitrile/water (45/55, v/v) at a flow rate of 2.5 mL/ min. The HPLC eluate was monitored in series for radioactivity and ultraviolet (UV) absorption (wavelength: 220 nm). Radiolabeling precursor 9-O-desmethyl-Ko143 and product [ 11 C]Ko143 eluted with retention times of 7.3 min and 15.9 min, respectively. The product fraction was diluted with water (100 mL) and passed over a pre-conditioned (5 mL of ethanol and subsequently 10 mL of water) C18 Sep-Pak Plus cartridge (Waters, Milford, MA, USA). The cartridge was then washed with water (10 mL) and [ 11 C]Ko143 was eluted with ethanol (3 mL).
The ethanol was then removed on a rotary evaporator. For i.v. injection into animals, the product was formulated at an approximate concentration of 370 MBq/mL in either 0.9% aq. saline solution/polysorbate 80 (100/0.1, v/v) for baseline scans, or in a mixture of sterile water/PEG300/polysorbate 80/DMSO (60/25/10/5, v/v/v/v) for scans in which unlabeled Ko143 was co-injected. Radiochemical purity and molar radioactivity of [ 11 C]Ko143 were determined by analytical radio-HPLC using an Agilent Eclipse XDB C18 (150 × 4.6 mm) column eluted with acetonitrile containing 0.1% aq. ammonium hydroxide solution/ 0.1% aq. ammonium hydroxide solution (45/55, v/v) at a flow rate of 1 mL/min. UV detection was performed at a wavelength of 228 nm and fluorescent detection with excitation and emission wavelengths set at 295 nm and 350 nm, respectively. The retention time of [ 11 C]Ko143 was 9.6 min on this HPLC system. (R)-[ 11 C]verapamil was synthesized as described elsewhere (Brunner et al., 2005) and formulated at a concentration of 370 MBq/mL in the same vehicle as [ 11 C]Ko143 for coinjection with unlabeled Ko143.
Animals
Female wild-type, Abcg2 
Abcg2
(−/−) mice with a FVB genetic background were obtained from Taconic Biosciences Inc. At the time of experiment, animals were 7-8 weeks old and weighed 25 ± 2 g. An acclimatization period of at least 1 week was allowed before the animals were used in the experiments. The study was approved by the national authorities (Amt der Niederösterreichischen Landesregierung) and study procedures were in accordance with the European Communities Council Directive of September 22, 2010 (2010/63/EU). 
Experimental design
PET imaging
Imaging experiments were performed under isoflurane anesthesia. Animals were warmed throughout the experiment and body temperature and respiratory rate were constantly monitored. Mice were placed in a custom-made imaging chamber and the lateral tail vein was cannulated for i. ]verapamil (47.7 ± 12.5 MBq in a volume of 0.15 mL, corresponding to 0.76 ± 0.06 nmol of unlabeled verapamil) mixed with a pharmacologic dose of unlabeled Ko143 (10 mg/kg). List-mode data were acquired with a timing window of 6 ns and an energy window of 250-750 keV. At the end of the PET scan, a blood sample (20-30 μL) was collected from the retro-orbital sinus and animals were sacrificed by cervical dislocation under deep anesthesia.
PET data analysis
The dynamic PET data were sorted into 23 frames, which incrementally increased in time length. PET images were reconstructed using Fourier re-binning of the 3-dimensional sinograms followed by a 2-dimensional filtered back-projection with a ramp filter giving a voxel size of 0.4 × 0.4 × 0.796 mm 3 . Using AMIDE software (Loening and 
a Ko143 was co-injected with radiotracer, same animals used as for baseline scan. b Ko143 vehicle was co-injected with radiotracer. c PET imaging performed at 2 h after i.v. administration of tariquidar. d No PET imaging performed. mouse. Brain is highlighted with a white broken line.
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Gambhir, 2003), left kidney, duodenum, intestine, liver, brain, gall bladder and urinary bladder were manually outlined on the PET images to derive concentration-time curves expressed in percent of the injected dose per gram or milliliter (%ID/g or %ID/mL). In addition, the left ventricle of the heart was outlined to obtain an image-derived blood curve. It was assumed, that the sum of radioactivity in the gallbladder, the duodenum and the intestine represented biliary radioactivity excreted from the liver. A graphical analysis method (integration plot) was used to estimate the rate constants for transfer of radioactivity from blood into brain (k uptake,brain , mL/min/g brain), liver (k uptake,liver , mL/ min/g liver) and kidney (k uptake,kidney , mL/min/g kidney), using data measured from 0.3 min-3.5 min after radiotracer injection, as described in detail elsewhere (Traxl et al., 2017) . Moreover, the rate constants for excretion of radioactivity from kidney into urine (k urine , min −1 ) and from liver into bile (k bile , min
) were determined from 4.5 min-45 min after radiotracer injection (Traxl et al., 2017) . Total distribution volume (V T ) of [
11 C]Ko143 in brain, liver and kidney was estimated by using
Logan graphical analysis over the interval of 6.25 min-45 min after radiotracer injection (Logan et al., 1990) . V T corresponds to the organto-blood ratio of radioactivity at steady state.
Analysis of radiolabeled metabolites
Radiolabeled metabolites of corresponding to 1.24 ± 0.53 nmol of unlabeled Ko143) was administered i.v. under isoflurane anesthesia. After a period of 20 min, blood was collected from the retro-orbital sinus and animals were sacrificed by cervical dislocation under deep anesthesia. Liver, kidneys, brain, bile and urine were collected. Blood was centrifuged to obtain plasma. Plasma proteins were precipitated by the addition of 1 μL acetonitrile per μL plasma. Liver, kidneys and brain were homogenized and proteins were precipitated with acetonitrile (1 mL per liver, 0.2 mL per kidneys/brain). Bile and urine were precipitated with acetonitrile (15 μL per 5 μL bile, 20 μL per 5 μL urine). All solutions were vortexed and then centrifuged (12,000g, 5 min, 4°C). Each supernatant (3 μL) and diluted radiotracer solution were spotted on thin-layer chromatography (TLC) plates (silica gel 60F 254 nm, 10 × 20 cm; Merck, Darmstadt, Germany) and plates were developed in ethyl acetate/ hexane (7/3, v/v). For detection, TLC plates were placed on multisensitive phosphor screens (Perkin-Elmer Life Sciences, Waltham, MA). Using a PerkinElmer Cyclone® Plus Phosphor Imager (Perkin-Elmer Life Sciences), the screens were scanned at a resolution of 300 dpi. Images were analyzed using Optiquant v5.0 software. The retardation factor (R f ) for [ 11 C]Ko143 was approximately 0.3.
In vitro autoradiography
One female FVB wild-type, Abcg2 (VWR Superfrost Plus) and stored at −80°C. The thawed brain slices were washed in phosphate-buffered saline solution containing 0.05% (v/v) polysorbate 20 (PBST) for 10 min. Subsequently, brain slices (n = 4) were incubated with either [ 11 C]Ko143 alone (2.7 nM) or with [ 11 C]Ko143 and unlabeled Ko143 (10 μM) at room temperature for 30 min. To remove non-specifically bound radiotracer, slices were washed twice for 5 min with a mixture of PBST and ethanol (80/20, v/v) and once for 2 min with distilled water. Washing steps were performed at 4°C. The slides were air-dried for 10 min at 37°C and exposed overnight to a multisensitive phosphor screen (MS, Perkin-Elmer Life Sciences, Waltham, MA, USA). The screens were then removed from the film cassettes under dim light. Using a Cyclone storage phosphor system (Perkin-Elmer Life Sciences, Waltham, MA, USA), the screens were scanned at a resolution of 600 dpi. Images were analyzed with OptiQuant v5.0 software.
Statistical analysis
Differences between groups were analyzed by one-way ANOVA followed by a Tukey's multiple comparison test using Prism 7 software (GraphPad Software, La Jolla, CA, USA). The level of statistical significance was set to a p value of < 0.05. All values are given as mean ± standard deviation (S.D.). (Fig. 4) . As the vehicle for formulation of unlabeled Ko143 was different from the vehicle used for radiotracer formulation, we examined one further group of wild-type mice, which was co-injected with Ko143 vehicle alone. In vehicle-co-injected wild-type mice, too, k uptake,brain and V T brain values were significantly higher than in wild-type mice which received [ mice co-injected with a pharmacologic dose of unlabeled Ko143 (Fig. 4) . Co-injection of unlabeled Ko143 abolished the differences seen in brain distribution between the four mouse genotypes when they were injected with a microdose of [ 
Results
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Influence of Abcg2 and Abcb1a/b on excretion of [ 11 C]Ko143
Over the time course of the PET scan, both hepatobiliary and urinary excretion of radioactivity occurred. Concentration-time curves of radioactivity in the liver and the kidney were similar for all four mouse genotypes (Fig. 5) . In wild-type mice, mean k uptake values were 0.689 mL/min/g tissue for the liver and 0.262 mL/min/g tissue for the kidney, which corresponded to extraction ratios of 0.69 for the liver and 0.06 for the kidney (assuming hepatic and renal blood flow rates in mice of 1.0 and 4.1 mL/min/g tissue, respectively) (Davies and Morris, 1993) . K uptake and V T values in the liver and kidney were similar for the four mouse genotypes (Figs. 7A,B and 8A,B) . We also estimated the rate constants for excretion of radioactivity from liver via bile into the intestine (k bile ) and from kidney into urine (k urine ) (Fig. S1 in the supplemental file). K bile values were not significantly different among the four mouse genotypes (Fig. 7C) , whereas k urine values were significantly lower in Abcg2 (−/−) and Abcb1a/b (−/−) Abcg2 (−/−) mice as compared with wild-type mice (Fig. 8C ). Co-injection of unlabeled Ko143 or Ko143 vehicle in wild-type mice caused a marked reduction in initial radioactivity uptake in the liver (Fig. 6A ) and significant decreases in both k uptake,liver and V T liver values (Fig. 7A,B) . In addition, the amount of radioactivity excreted into the intestine was significantly decreased, with 1.9-and 2.4-fold lower k bile values in wild-type mice co-injected with unlabeled Ko143 or Ko143 vehicle, respectively, as compared with wild-type mice injected with [ 11 C]Ko143 alone (Fig. 7C ). In the kidneys, co-injection of unlabeled Ko143 significantly decreased k uptake,kidney values (Fig. 8A) . Moreover, k urine values were almost decreased to zero for co-injection of both unlabeled Ko143 and Ko143 vehicle (Fig. 8C) .
Assessment of radiolabeled metabolites of [ 11 C]Ko143
In separate groups of wild-type and Abcb1a/b detected, and only radiolabeled metabolites were found in the urine (Table 2) . mice a significant increase in binding (+41%) was observed.
Discussion
PET imaging of ABC transporters
Two approaches have been proposed for the development of PET tracers for ABC transporters Raaphorst et al., 2015) . The first approach, which uses radiolabeled substrates to visualize the function of transporters, has produced very useful radiotracers such as (R)- The second approach uses compounds which bind to the transporter without being transported and which should theoretically allow for mapping the density (abundance) of the transporter in different tissues. This second approach may potentially be very useful, in particular for tissues which are protected by ABC transporters, such as the brain, for which radiolabeled transporter substrates afford very low imaging signals. However, this approach has remained unsuccessful so far, presumably due to the low density of ABC transporters, in particular in the brain (~1 nM), combined with insufficiently high binding affinities of the tested compounds (Bauer et al., 2013; Kannan et al., 2013; Müllauer et al., 2013) . Based on available in vitro data with [ imaging in wild-type as well as in Abcg2 and/or Abcb1a/b knockout mice to assess the influence of Abcg2 and Abcb1a/b on the distribution of [ 11 C]Ko143 to different tissues which express Abcg2 (kidney, liver and brain). Moreover, we assessed if these transporters play a role in the excretion of [ 11 C]Ko143. PET is a powerful tool to assess the interaction of drugs with ABC and SLC transporters (Kusuhara, 2013; Testa et al., 2015; Langer, 2016) . A great advantage of small-animal PET studies in mice is that the entire animal is within the field of view of the PET scanner, so that kinetic information on radiotracer distribution can be obtained from all organs and tissues in a single PET scan. We generated an image-derived blood curve and used graphical analysis approaches to obtain pharmacokinetic parameters, which were shown in previous studies to be sensitive to membrane transporter function in different organs (V T , k uptake , k bile and k urine ) (Bankstahl et al., 2008; Takashima et al., 2013; Shingaki et al., 2015; Traxl et al., 2015; Traxl et al., 2017) . Image-derived blood radioactivity concentrations overestimated the true blood values measured in a gamma counter, most likely due to spillover/partial volume effects. However, as the magnitude of these spillover/partial volume effects is unlikely to differ among different mouse groups, our analytical approach appears valid to assess relative differences in outcome parameters between the studied mouse groups. An advantage of k uptake is that this parameter is derived from early PET data (< 5 min after radiotracer injection) and should therefore be minimally affected by tissue uptake of radiolabeled metabolites. [ 11 C]Ko143 was extensively metabolized, and radiolabeled metabolites were detected along with unchanged [ 11 C]Ko143 in all investigated tissues (brain, liver and kidney) ( Table 2 ). Although we were not able to verify the identity of the radiolabeled metabolites, it is reasonable to assume -based on previous data (Weidner et al., 2015; Liu et al., 2017 ) -that they mainly consisted of 11 C-labeled Ko143 free acid. These radiolabeled metabolites may either be formed by plasma carboxylesterases and then taken up into different tissues, or they may also be directly formed by tissue carboxylesterases (Liu et al., 2017) .
Influence of Abcg2 and Abcb1a/b on brain distribution of [ 11 C]Ko143
At the BBB, ABCB1 and ABCG2 cooperate with each other in limiting brain distribution of dual ABCB1/ABCG2 substrates, such as tyrosine kinase inhibitors (Kodaira et al., 2010; Agarwal et al., 2011) . Only when both ABCB1 and ABCG2 are knocked out or inhibited are substantial increases in brain distribution of dual ABCB1/ABCG2 substrates achieved. We detected no differences in brain distribution of Ko143 stimulated human ABCB1 ATPase activity, suggesting substrate affinity for ABCB1 (Weidner et al., 2015) . On the other hand, the same authors found no in vitro transport of [ 3 H]Ko143 in human ABCB1-and mouse Abcb1a-overexpressing cells, which contradicts our in vivo PET results (Weidner et al., 2015) . This makes the selection of candidate compounds for the development of PET tracers for ABC transporters very challenging, as in vitro data, even when acquired with low concentrations of 3 H-labeled compounds (Weidner et al., 2015; Raaphorst et al., 2017) , do not necessarily predict the in vivo behavior of PET tracers.
We were interested in finding out if [ 11 C]Ko143 also showed Abcb1a transport at the murine BBB when administered at pharmacologically relevant doses. To this end, we studied brain distribution of [ 11 C]Ko143-derived radioactivity in wild-type and transporter knockout mice which were co-injected with unlabeled Ko143 at a dose which was previously shown to inhibit Abcg2 at the murine BBB (Wanek et al., 2012; Bakhsheshian et al., 2013) . Co-injection of unlabeled Ko143 (10 mg/kg) abolished the differences in brain distribution of radioactivity between the four mouse genotypes which were observed when they were injected with a microdose of [ 11 C]Ko143 (Fig. 4) . Similarly, co-injection of Ko143 (10 mg/kg) with the validated ABCB1 substrate radiotracer (R)-[
11 C]verapamil (Luurtsema et al., 2003; Römermann et al., 2013 ) increased brain distribution of (R)- [ 11 C] verapamil to comparable levels as in tariquidar pre-treated wild type mice and in Abcb1a/b (−/−) mice (Fig. S2 of the supplemental file). We found that the observed Abcb1a inhibitory effect of Ko143 could be attributed to the vehicle used for formulation of Ko143 rather than to Ko143 itself (Fig. 4) . Ko143 is a highly lipophilic compound with very poor aqueous solubility, requiring co-solvents and surfactants for solubilization. The vehicle which was used in our study (sterile water/ PEG300/polysorbate 80/DMSO, 60/25/10/5) was adopted from previously published work (Shimanovich et al., 2010) . It ensured that Ko143 remained in solution for the required amount of time while containing safe levels of excipients. It is well known that pharmaceutical excipients can exert inhibitory effects on membrane transporters such as ABCB1 (Sosnik, 2013) . For instance, Hugger et al. reported that PEG300 (20%, v/v) caused almost complete in vitro inhibition of ABCB1 activity in both Caco-2 and MDR1-MDCK cell monolayers, whereas polysorbate 80 (0.05%, w/v) only partially inhibited ABCB1 activity in Caco-2 cells (Hugger et al., 2002 ). Our results emphasize that possible excipient effects need to be considered when assessing drug-drug interactions in vivo, in particular for poorly soluble compounds. The Ko143 vehicle employed in our work precluded an assessment of whether Ko143 transport by Abcb1a at the mouse BBB is saturated at pharmacologic Ko143 doses. Allen et al. reported a half-maximum effect concentration of 1.0 μM for in vitro reversal of ABCB1-mediated paclitaxel resistance by Ko143 (Allen et al., 2002) . The reported plasma concentration of Ko143 in mice at 1 h after i.v. administration of a dose of 10 mg/kg is 420 nM (Zhang et al., 2011) . The unbound fraction of Ko143 in rat plasma is 0.0293 (Liu et al., 2014) . Assuming that plasma protein binding does not differ between rats and mice, the unbound plasma concentration of Ko143 in mice at 1 h after an i.v. 10 mg/kg dose can be estimated as 12 nM, which is far too low to achieve ABCB1 inhibition. This is also supported by our own previous results, in which no increase in brain uptake of the dual Abcb1a/Abcg2 substrate [ 11 C] tariquidar was observed in Abcg2 (−/−) mice pre-treated at 1 h before PET with 10 mg/kg Ko143 (Wanek et al., 2012 Based on these data, it cannot be entirely excluded that Ko143 binds to Abcg2; the affinity of Ko143 to Abcg2 may be too low to achieve an Abcg2-specific binding signal in brain tissue. The ABCG2/Abcg2-overexpressing cell lines used in the previously published in vitro experiments may express higher levels of ABCG2/Abcg2, so that ABCG2/ Abcg2-specific binding was measurable in vitro (Weidner et al., 2015) . We also assessed distribution of [ 11 C]Ko143-derived radioactivity to the kidney and liver, which have an 168-and 7-fold higher density of Abcg2, respectively, as compared with brain microvessels (Dallas et al., 2016) . In these two organs, too, there was no difference in k uptake and V T values between wild-type and Abcg2
(−/−) mice, suggesting a lack of Abcg2-specific binding. Remarkably, co-injection of both Ko143 and Ko143 vehicle significantly reduced k uptake,liver values in wild-type mice, pointing to an inhibition of basolateral uptake transporters in hepatocytes (Figs. 6A and 7A). As Ko143 has been found to inhibit human SLCO transporters (SLCO1B1 and SLCO2B1) (Karlgren et al., 2012) , it is tempting to speculate that [ 11 C]Ko143 and possibly its radiolabeled metabolites are taken up into the mouse liver by the murine orthologues of these transporters. Since Abcg2 mediates excretion of compounds from the liver via bile into the intestine and from the kidneys into urine, we also estimated k bile and k urine values of radioactivity following injection of [ (Table 2) , Abcg2 most likely mediates urinary excretion of one or more of these [ 11 C]metabolites. Interestingly, Ko143 vehicle strongly inhibited urinary as well as intestinal excretion of radioactivity, further emphasizing that effects of pharmaceutical excipients can be observed in vivo in multiple organs. As PEG300 and polysorbate 80 are commonly used excipients, their inhibitory effects on ABC and SLC transporter need to be taken into account for in vivo drug-drug interaction studies to avoid a misinterpretation of transporter effects.
Conclusion
We assessed the suitability of [ 11 C]Ko143 to measure the density of Abcg2 in different mouse tissues and failed to detect any Abcg2-specific binding of the radiotracer, which highlights the challenges associated with the development of PET tracers to measure ABC transporter densities in tissues. We discovered that [ 11 C]Ko143 and possibly its radiolabeled metabolites are transported by Abcb1a and not by Abcg2 at the murine BBB, and that Abcg2 contributes to urinary excretion of the radiolabeled metabolites of [ 11 C]Ko143. Moreover, we observed pronounced effects of the vehicle used for formulation of Ko143 on tissue distribution and excretion of [ 11 C]Ko143-derived radioactivity, which emphasizes the importance of considering the effects of pharmaceutical excipients on ABC and SLC transporters for in vivo studies.
